Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials.
Prostate cancer is a multistep process in which progression rather than initiation may be the rate-limiting step. A strong possibility is that prostatic intraepithelial neoplasia lesions that switch to angiogenic phenotype eventually progress to cancer. However, it is a challenging task to quantitate angiogenesis in preneoplastic lesions. A promising approach to measuring angiogenesis involves real-time TaqMan polymerase chain reaction to quantitate mRNAs encoding a panel of angiogenesis markers. This highly sensitive molecular technique has potential for quantitating angiogenesis in clinical settings and can be used as a high-throughput screening procedure in prostate cancer clinical trials.
Ali
I U
IU
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852 , USA.
Senger
D R
DR
Smith
L E
LE
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D018450:Disease Progression; D016228:Endothelial Growth Factors / Q000378:metabolism; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D006801:Humans; D008222:Lymphokines / Q000378:metabolism; D008297:Male; D008545:Melanoma / Q000378:metabolism; D051379:Mice; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000378:metabolism; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods*; D019048:Prostatic Intraepithelial Neoplasia / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism; D014183:Transplantation, Heterologous; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D015415:Biomarkers; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors